Table 5.
Statistical analyses of the IVSA profile in all lines (Fig. 4)
| Item | Figure | Experiment | Statistical test | Effect or interaction | Main effect | flMOR | D1flMOR | D2flMOR | A2aflMOR | ChATflMOR |
|---|---|---|---|---|---|---|---|---|---|---|
| a | 3A | Remifentanil acquisition | LMM | AL day effect | p < 0.0001, χ2 = 21.017 | n = 15 | n = 12 | n = 10 | n = 12 | n = 12 |
| b | 3C | Remifentanil acquisition | LMM | RNFS earned day effect | p < 0.0001, χ2 = 19.132 | |||||
| c | 3D | Remifentanil acquisition | LMM | Percent AL presses day effect | p < 0.01, χ2 = 9.730 | |||||
| d | 3E | Oxycodone maintenance | LMM | AL presses × Treatment Oxycodone vs. Saline | p < 0.001, χ2 = 10.926 | p < 0.001, χ2 = 11.601, n = 14 | p < 0.01, χ2 = 6.764, n = 9 | p < 0.001, χ2 = 12.806, n = 9 | p < 0.01, χ2 = 10.545, n = 8 | p < 0.001, χ2 = 13.68, n = 7 |
| e | 3G | Oxycodone maintenance | LMM | RNFS × treatment Oxycodone vs. Saline | p < 0.0001, χ2 = 16.051 | p < 0.001, χ2 = 11.435 | p < 0.01, χ2 = 8.434 | p < 0.01, χ2 = 9.339 | p < 0.001, χ2 = 10.981 | p < 0.001, χ2 = 14.648 |
| f | 3G | Oxycodone maintenance | LMM | Percent AL presses treatment × day oxycodone vs saline | p < 0.0001, χ2 = 34.81 | p < 0.0001, χ2 = 15.957 | p < 0.0001, χ2 = 20.334 | p < 0.01, χ2 = 7.918 | p < 0.0001, χ2 = 16.952 | p < 0.0001, χ2 = 19.941 |
| g | 3E | Extinction; transition | LMM | AL presses treatment × day oxycodone vs. saline | p < 0.01, χ2 = 8.296 | |||||
| h | 3G | Extinction; transition | LMM | RNFS treatment × day oxycodone vs. saline | p < 0.01, χ2 = 7.047 | |||||
| i | 3E | Extinction; transition | LMM | AL presses day effect within oxycodone treated |
p < 0.0001, χ2 = 29.255 | |||||
| j | 3F | Extinction; transition | LMM | IAL presses day effect within oxycodone treated |
p < 0.01, χ2 = 9.396 | |||||
| k | 3G | Extinction; transition | LMM | RNFS day effect within oxycodone treated | p < 0.0001, χ2 = 25.725 | |||||
| l | 3G | Extinction | LMM | AL presses × genotype within oxycodone treated | p = 0.050, χ2 = 9.480 | N.A. | N.S. | N.S. | p = 0.043 | N.S. |
| m | 3G | Extinction | LMM | IAL presses × genotype within oxycodone treated | p = 0.057, χ2 = 9.148 | N.A. | N.S. | N.S. | p = 0.025 | N.S. |
| n | 3G | Extinction | LMM | RNFS earned × genotype within oxycodone treated | p = 0.018, χ2 = 11.934 | N.A. | N.S. | N.S. | p = 0.031 | p = 0.007 |
| o | 3G | Extinction | LMM | RNFS earned day effect |
p < 0.001, χ2 = 12.979 |
p < 0.001, t(50) = –4.124 |
p < 0.001, t(53) = –3.964 |
p < 0.001, t(55) = –3.946 |
p < 0.001, t(55) = –3.135 |
p < 0.001, t(56) = –2.726 |
| p | 3I | Last day AL oxycodone | Two-way ANOVA | Genotype × time | F(480,5160) = 0.45, p > 0.99 | |||||
| q | 3L | Last day oxycodone RNFS | Two-way ANOVA | Genotype × time | F(480,4920) = 0.2, p > 0.99 | |||||
| r | 3J | First day extinction AL | Two-way ANOVA | Genotype × time | F(480,4920) = 1.44, p < 0.0001 | Reference genotype | N.S. | N.S. | p < 0.05 | N.S. |
| s | 3M | First day extinction RNFS | Two-way ANOVA | Genotype × time | F(480,4800) = 1.66, p < 0.0001 | Reference genotype | N.S. | N.S. | p < 0.05 | p < 0.05 |
| t | 3J | Third day extinction AL | Two-way ANOVA | Genotype × time | F(480,5160) = 0.42, p > 0.99 | Reference genotype | N.S. | N.S. | N.S. | N.S. |
| u | 3M | Third day extinction RNFS | Two-way ANOVA | Genotype × time | F(480,5280) = 2.02, p < 0.0001 | Reference genotype | N.S. | N.S. | N.S. | p < 0.05 and p < 0.01 |
N.S.: not significant, N.A: not applicable.